| Name | Title | Contact Details |
|---|
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Quark Pharmaceuticals is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.
Linical is a leading CRO conducting clinical trials in oncology, infectious disease, and CNS. Let us support your journey, the right way. Learn more here!
Interspond is a Trial Management Organization (TMO) that works with a network of multi therapeutic sites across the country to facilitate clinical and pharmaceutical research and trials.